Financial Wire

Venture Energy, Shenji Energy Sign Green Methanol Supply Deal

-- Venture Energy and Shanghai Shenji Energy & Environmental Technology Company have signed a green methanol procurement and supply deal to strengthen the supply of low-carbon marine fuel, the companies said on Monday.

Under the agreement, Venture Energy will purchase ISCC EU-certified green methanol from Shenji Energy, which complies with the European Union's Renewable Energy Directive, with the first shipments scheduled for H1 2026.

The fuel is produced from biomass feedstocks, including municipal waste, crop straw, and livestock manure, and is designed to deliver significant reductions in lifecycle carbon emissions.

The companies said the product is intended to help shipping operators meet tightening regulatory requirements, including the EU Emissions Trading System and the FuelEU Maritime Regulation.

Venture Energy plans to leverage its shipping network and Hong Kong's position as a regional maritime hub to connect Chinese clean fuel producers with global marine fuel buyers. It also plans to offer supply-chain services to support end-to-end delivery of green marine fuels from mainland China production sites to bunkering ports across Asia.

Shenji Energy said it will supply ISCC-certified biomethanol along with verified sustainability certificates to ensure traceability across the value chain.

The partnership also includes cooperation on sourcing biogas feedstock and ISCC certification systems, which the companies said will support a standardized, traceable trading framework for renewable marine fuels.

相关文章

Asia

National Storage REIT 表示,新南威尔士州法院已批准 Brookfield 和 GIC 的收购计划

根据周二提交给澳大利亚证券交易所的文件,National Storage REIT(ASX:NSR)确认,新南威尔士州最高法院已批准股份重组方案,并为信托方案提供了司法建议,从而使由Brookfield Funds和GIC牵头的财团能够继续推进对该公司所有合订证券的收购。 根据提交给澳大利亚证券和投资委员会的文件,该方案已正式生效,公司证券预计将于周二收盘后暂停交易。 文件还补充道,该方案的股权登记日为4月29日,实施日期定于5月8日,届时证券持有人将收到方案对价。

$ASX:NSR
Asia

Starpharma公司称美国FDA支持其癌症放射疗法候选药物的首次人体试验;股价上涨7%。

据周二提交给澳大利亚证券交易所的文件显示,Starpharma Holdings(ASX:SPL)已收到美国食品药品监督管理局(FDA)对其DEP HER2放射疗法候选药物首次人体I期临床试验方案的积极反馈。 该公司正在开发该候选药物,用于治疗某些胃癌/胃食管交界处癌以及其他既往接受过靶向治疗的晚期癌症患者。 美国FDA的反馈支持启动I期临床试验的计划,该试验预计将于今年下半年开始。 Starpharma表示,FDA还确认该放射疗法候选药物针对的人群存在显著的未满足医疗需求,这表明该药物有可能获得快速通道资格或其他加速开发途径。 该公司股价在周二的交易中上涨了7%。

$ASX:SPL
Asia

韩国央行任命新行长

韩国央行周二宣布任命申玄松为新任行长,接替李昌镕担任这一最高金融职位。 申玄松将在未来四年领导韩国央行的货币政策和理事会工作。他将于5月28日主持首次政策会议。 在就职演说中,申玄松表示,面对日益加剧的不确定性、高通胀以及中东战争带来的供给冲击,韩国必须努力通过谨慎灵活的货币政策操作实现“物价稳定和金融稳定”。 申玄松还表示,他将重点推进韩元国际化,因为这对于构建货币基础设施至关重要。 韩国央行将推行24小时外汇市场操作,并建立离岸韩元结算系统。这些举措将提高外汇交易的便捷性和稳健性,使其符合国际标准。此外,这些努力还将有助于韩元计价的资本和贸易交易。

$^KOSDAQ$^KS11